Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 6/20 | 0.58 |
| ▸ | WDR5 | P61964 | 2/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | SLC10A6 | Q3KNW5 | 2/20 | 0.45 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.45 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.45 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5598059 | 0.86 | CCR9 (0.62) | CCR9WDR5KDM1ASLC10A6SLC10A2 | |
| SCHEMBL5597922 | 0.85 | CCR9 (0.56) | CCR9KDM1AMETAP2 | |
| SCHEMBL5597849 | 0.84 | CCR9 (0.55) | CCR9DDR1 | |
| SCHEMBL5597986 | 0.83 | CCR9 (0.58) | CCR9WDR5KDM1ASLC10A6SLC10A2 | |
| SCHEMBL14601702 | 0.81 | CCR9 (0.56) | CCR9KDM1A | |
| SCHEMBL5597820 | 0.80 | CCR9 (0.72) | CCR9WDR5KDM1ASLC10A6SLC10A2 | |
| SCHEMBL14601699 | 0.80 | CCR9 (0.63) | CCR9WDR5KDM1ASLC10A6SLC10A2 | |
| SCHEMBL5597824 | 0.79 | CCR9 (0.70) | CCR9WDR5KDM1ASLC10A6SLC10A2 | |
| SCHEMBL3243266 | 0.79 | CCR9 (0.70) | CCR9WDR5KDM1ASLC10A6SLC10A2 | |
| SCHEMBL5597984 | 0.78 | KCNA5 (0.56) | CCR9SLC10A6SLC10A2SLC10A1METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1815860-A2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1465638-B1 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORP (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
| US-7119120-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1465638-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040019113-A1 | Phosphate transport inhibitors | GELTEX PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2003057225-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019113-A1 | Phosphate transport inhibitors | SLC34A1, SLC34A2, SLC20A1 | CCR9 3886/4885WDR5 600/4885KDM1A 4216/4885 |
| US-20070021509-A1 | Phosphate transport inhibitors | SLC34A2, SLC34A1, SLC20A1 | CCR9 4370/4885WDR5 1437/4885KDM1A 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.